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Abstract
Introduction: Neuroinflammation has been established to be part of the neuropathological changes in Parkinson’s
disease (PD) and atypical parkinsonism (APD). Activated microglia play a key role in neuroinflammation by release
of cytokines. Evidence of the disparity, if any, in the neuroinflammatory response between PD and APD is sparse. In
this study, we investigated CSF cytokine profiles in patients with PD, multiple system atrophy (MSA), or progressive
supranuclear palsy (PSP).
Methods: On a sensitive electrochemiluminescence-based platform (Quickplex, Meso Scale Discovery®), we
examined a panel of C-reactive protein (CRP) and eight selected cytokines, IFN-γ, IL-10, IL-18, IL-1β, IL-4, IL-6,
TGF-β1, and TNF-α, among patients with PD (n = 46), MSA (n = 35), and PSP (n = 39) or controls (n = 31). Additionally,
CSF total tau protein levels were measured as a marker of nonspecific neurodegeneration for correlation estimates.
Results: CRP and the pro-inflammatory cytokines TNF-α, IL-1β, and Il-6 were statistically significantly elevated in MSA
and PSP patients compared to PD patients but not compared to control patients. No analytes differed statistically
significantly between MSA and PSP patients. The best diagnostic discrimination, evaluated by ROC curve (AUC 0.
77, p = 007, 95% CI 0.660–0.867), between PD and MSA patients was seen for a subset of analytes: CRP, TNF-α, IL-
1β, and IFN-γ.
Conclusion: Among the investigated cytokines and CRP, we found a statistically significant increase of microglia-
derived cytokines in MSA and PSP patients compared to PD patients.
Keywords: Parkinson’s disease, Multiple system atrophy, Progressive supranuclear palsy, Cerebrospinal fluid,
Biomarkers, Cytokines, C-reactive protein
Background
Neuroinflammation co-exists with neurodegeneration in
Parkinson’s disease (PD), atypical parkinsonism (APD),
and neurodegenerative disorders in general [1]. PD is
neuropathologically characterized by a progressive loss
of dopaminergic neurons in the substantia nigra [2], and
postmortem studies have identified activated microglia
in substantia nigra linking PD to neuroinflammatory
changes [3]. In the pathogenesis of the atypical Parkin-
son disorders, multiple system atrophy (MSA), and pro-
gressive supranuclear palsy (PSP), microglia activity also
accompanies neurodegeneration [4, 5]. Little evidence is
available on whether disparity exists in neuroinflamma-
tion between PD and APD.
Microglia, the resident innate immune cells of the
brain, act as macrophages and constitute 10–20% of glial
cells [6] and function through a network of secreted
cytokines and chemokines acting as signaling molecules
upon activation. Activated microglia may take a pro-in-
flammatory or anti-inflammatory phenotype.
Cytokines can be detected in the cerebrospinal fluid
(CSF), and previous studies have demonstrated that
IL-1β and IL-6 [7], TNF-α [8], and IL-8 [9] are elevated
in the CSF in PD patients compared to controls. Other
studies have, however, demonstrated an opposing pat-
tern [10], and the biomarker potential of CSF cytokines
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is thus unclear. To what extent the increase in cyto-
kine levels reflects specific inflammatory mechanisms
or is a result of a quantitative increase in brain path-
ology is unknown.
In this study, we investigated the expression of se-
lected cytokines in CSF in PD, MSA, or PSP, compared
to controls. The aim of the study was to evaluate differ-
ences in cytokine profile across PD and two APDs with
differences in neuropathological hallmarks as well as
evaluate the potential of cytokines to differentiate be-
tween MSA and PD (two synucleinopathies).
Methods
Patients
We included patients with PD, MSA, PSP, and symp-
tomatic controls (SC; definition [11]). All patients were
included consecutively from the tertiary Movement
Disorders Centre at the Department of Neurology,
Bispebjerg University Hospital, from October 2007 to
October 2015. For inclusion, structural neuroimaging
(computed tomography (CT) scan or magnetic reson-
ance imaging of the brain) and/or a DaTSCAN as part
of the diagnostic work-up was required. All diagnoses
were assigned by an experienced movement disorder
specialist (KW), blinded to laboratory results, and all
included patients met the clinical criteria for possible
or probable diagnosis of the study diseases at sampling
[12–14]. After diagnostic follow-up, only samples col-
lected from patients fulfilling the criteria for probable
disease at the time of follow-up was included. Follow-
up time was noted as time from sampling until death
or most recent recorded clinical control.
The SCs were included through the Neurological
Emergency Department, Bispebjerg University Hospital.
Eligible SCs included individuals with isolated acute
onset headache suspected of subarachnoid hemorrhage
and individuals with subsequently normal CT scan and
neurological examination, who required lumbar punc-
ture as part of diagnostic workout, and CSF without
xanthochromia.
Basic characteristics, Hoehn and Yahr (HY) score,
Levodopa Equivalent Doses (LED), data on use of
anti-inflammatory drugs (nonsteroidal anti-inflammatory
drugs (as chronic therapy), glucocorticoids, disease-
modifying anti-rheumatic drugs, biological pharmaceuti-
cals, antimetabolites, cyclophosphamide), and Charlson
Comorbidity Index scores [15] were obtained. As a
proxy for the degree of nonspecific neurodegeneration,
we measured total Tau (t-tau) protein in the CSF. To in-
vestigate potential leakage of the blood-brain barrier, the
plasma/CSF albumin ratio was assessed. CSF samples
were analyzed for routine parameters: cell count, total
protein level, and hemoglobin contamination.
Sampling
Lumbar puncture was primarily performed using an
atraumatic needle (22G, Smiths Medical). CSF was col-
lected in a polypropylene tube placed on ice. Samples
were centrifuged (10 min., 2000g, 4 °C within 30 min)
and the supernatant aliquoted in 400-μl polypropylene
tubes and placed at − 80 °C within 90 min.
Laboratory methods
A multiplex panel consisting of CRP and eight cyto-
kines (IFN-γ, IL-10, IL-18, IL-1β, IL-4, IL-6, TGF-β1,
and TNF-α) was applied. We aimed to include
microglia-derived cytokines representing both pro-in-
flammatory and anti-inflammatory pathways. Further-
more, inflammatory markers which had previously
been studied in parkinsonian syndromes were in-
cluded based on a review of existing literature. The
cytokines were quantified using an in-house assay and
a sensitive electrochemiluminescence-based platform
(Quickplex, Meso-Scale Discovery®, MD). In short, the
specific antibodies were biotinylated, bound to differ-
ent linkers 1–8 (Meso-Scale, Maryland), mixed to-
gether to the concentrations 10 μg/ml per antibody,
added to each U-plex plate well (50 μl/well), and
incubated for 1 h. After washing with washing buffer
(PBS containing 0.05% Tween 20), 25 μl undiluted
CSF from each sample was added, the plates were sealed
and incubated with shaking for 2 h, and washed three
times. The corresponding detection antibodies were
sulfo-tagged using MSD Gold Sulfo-tag NHS-Ester
(Meso-Scale, R91AO-2), added 25 μl to each well, conc.
0.1 μg/ml, and incubated with shaking for 2 h. Finally, the
plates were washed, 150 μl 2× Read buffer T (Meso-Scale
R92TC) was added per well, and immediate readings were
performed using a QuickPlex reader. Concentrations were
calculated with Discovery Workbench software (Meso--
Scale) from calibration curves using four-parameter logis-
tic fit. All antibodies were purchased from RnDsystems.
T-tau levels were measured in 100 μl of CSF using
a fully validated enzyme-linked immunosorbent assay
(ELISA) kit (Innotest®, Fujiriebio Diagnostics AB,
Göteborg, Sweden) according to the manufacturer’s
protocols. The plasma/CSF albumin ratio was assessed
by immunonephelometry on a ProSpec BN instru-
ment (Siemens).
Statistical analysis
Statistical analyses were performed with SAS Enter-
prise Guide 7.1 and GraphPad Prism 6. Demographics
and analytes were compared by Kruskal-Wallis test for
medians, Pearson chi-square for proportions, or one-way
ANOVA if data followed an approximative Gaussian dis-
tribution. All cytokine levels fitted a non-normal distribu-
tion. To minimize risk of confounding, a multivariate
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generalized linear model adjusting for age, gender,
and use of any anti-inflammatory drug was fitted with
log-transformed values of cytokines. Group-wise com-
parisons were adjusted with the Tukey correction.
Univariate correlations were performed with Spearman
correlations. The Bonferroni correction was used to cor-
rect for multiple comparisons. However, in a few sam-
ples, the measured concentrations were reported under
the detection limit for the assay and were noted as half
of the detection limit for the analysis.
Receiver operating characteristic (ROC) curves were
constructed to evaluate the biomarker potential of each
investigated analyte and for the best subset (maximum
4). The best subset of analytes was identified in a logistic
regression model by score selection (SAS Enterprise
Guide 7.1).
Results
The study population comprised 154 patients (70
women and 84 men). Medical history review revealed re-
mitting multiple sclerosis (SC), ulcerative colitis (SC),
and polymyalgia rheumatica (PSP) in three patients who
were excluded from further analysis, leaving 151 patients
for final analysis. Demographics are presented in
Table 1.
Groups differed significantly in age, gender, and dis-
ease duration at sampling. SCs were younger than
disease groups, and PD patients had longer disease dur-
ation. Except for IL-18 and TGF-β1, all investigated
cytokines correlated positively with age, but no correl-
ation with disease duration or LED was observed
(Additional file 1: Table S1). With the exception of
IL-4, t-tau did not correlate statistically significantly
with analytes. Disease duration and HY did not correl-
ate (r = − 0.07, p = 0.42) in any groups (PD r = 0.25, p =
0.09; MSA r = 0.12, p = 0.48; PSP r = 0.15, p = 0.33).
CSF concentrations of analytes
Overall, we found statistically significantly higher con-
centrations of CRP, TNF-α, IL-1β, IL-4, and IL-6 in
MSA and PSP compared to PD. In addition, the level of
Il-10 was statistically significantly different between PSP
and PD. INF- γ, IL-18, and TGF- β1 did not differ sig-
nificantly between the patient groups.
In addition, except for IL-4, no analytes exhibited a
statistically significantly different distribution between
PD and SC. Likewise, no analyte differed statistically sig-
nificantly between SC and APD. Box plots are presented
in Fig. 1.
The albumin CSF/plasma ratio was similar in dis-
ease groups and, as expected, somewhat reduced
among the SC patients, although not statistically sig-
nificant (p = 0.137). Biochemical data are presented in
Table 2.
Diagnostic performance
Investigated cytokines were evaluated with ROC
curves assessing their individual ability to differentiate
between the study groups. CRP was the best single
analyte to discriminate between PD and MSA (AUC
0.70, p value 0.005, 95% CI 0.591–0.817). No other
analyte achieved AUC > 0.70 (data not shown). CRP
and a cytokine set (TNF-α, IL-1β, IFN-γ) was identi-
fied as the best subset to discriminate between MSA
and PD (AUC = 0.77, p = 0.007, 95% CI 0.660–0.867).
ROC curves (Fig. 2) including t-tau in the model
yielded a best subset of CRP, TNF-α, IFN-γ, and t-tau
(AUC 0.81, p < 0.001, 95% CI 0.713–0.901).
Il-1β (AUC 0.73, p value 0.019, 95% CI 0.624–0.837)
was the best analyte to discriminate between PD and
PSP followed by IL-4 (AUC 0.72, p value 0.012, 95% CI
0.611–0.830), CRP (AUC 0.70, p value 0.004, 95% CI
0.592–0.814), and TNF-α (AUC 0.70, p value 0.004, 95%
CI 0.583–0.808). A subset of four analytes did not yield
higher AUC between PD and PSP (data not shown).
Discussion
We examined a selection of CSF cytokines among patients
with PD or atypical Parkinson disorders, MSA, and PSP.
To our knowledge, this is the first study of differences in
Table 1 Demographics
PD MSA PSP Controls (SC)
N (male/female)a 30/16 13/22 25/14 15/16
Age at sampling (years), mean (SD)b 64.46 (11.5) 63.48 (7.8) 69.77 (5.1) 45.48 (17.7)
Disease duration at puncture (months), mean (SD)b 83.78 (45.9) 63.51 (23.8) 54.8 (28.4) –
Follow-up time (months), mean (SD)b 11.3 (9.2) 18.2 (16.5) 18.9 (14.6) –
H + Y stages, median, IQR 2 (2) 3 (1) 3 (1) –
Comorbidity, Charlson score (age-adjusted) 0.81 0.63 1.10 0.60
Levodopa Dose Equivalents, mg, SDb 596.8 (382.6) 712.28 (552.7) 324.2 (369.0) –
aKruskal-Wallis or one-way ANOVA p < 0.05, Bonferroni corrected
bp < 0.05 chi-square
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CSF cytokine expression profiles comparing PD patients
with those suffering from atypical Parkinsonism.
Our key findings included (1) increased concentrations
of CRP and cytokines IL-1β, TNF-α, IL-6, and Il-4
among both MSA and PSP patients compared to PD
patients, but not compared to SCs; (2) except for IL-4,
no significant differences between PD and SCs; and (3)
the best diagnostic discrimination between PD and
MSA, evaluated by ROC curves, was found with a com-
bination of analytes.
PD and MSA are both characterized by accumulation
of abnormally aggregated alpha-synuclein (AS) in Lewy
bodies and glial cytoplasmic inclusions, respectively [16].
Microglia is believed to be the key player in neuroin-
flammation in alpha-synucleinopathies. PSP, however,
belongs to the tauopathies, where the protein Tau con-
stitutes the neuropathological hallmark [17]. Although
MSA and PSP present with differences in the neuropath-
ology, both diseases are rapidly progressing atypical Par-
kinson disorders with severe symptomatology, and in
Fig. 1 Box plots of CRP and eight selected cytokines plotted in diagnostic groups. The plots are presented without outliers. p values are adjusted
for age, gender, and use of anti-inflammatory medication
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our study, MSA and PSP exhibited similar patterns in
CRP and cytokine expression, although PSP presented
with the overall highest values (non-significant) of mea-
sured cytokines.
Activated microglia may take either an anti- or
pro-inflammatory phenotype responsible for both pro-
tective and regenerative actions, as well as maintenance
of chronic inflammation, possibly enhancing neurode-
generation [18]. TNF-α, IL-1β, and IL-6 are secreted by
activated microglia and represent the pro-inflammatory
pathway, and in our study, these cytokines were all sig-
nificantly higher among MSA/PSP compared to those
with PD. INF-γ stimulates the pro-inflammatory pheno-
type [18] and was not significantly different among
groups. IL-10 represents the anti-inflammatory pathway
and was significantly increased in PSP compared to PD,
and likewise, IL-4 was also significantly increased in
MSA/PSP compared to those with PD. IL-4 stimulates
the anti-inflammatory phenotype [19]. Hence, our data
may indicate an upregulation of microglia-derived cyto-
kines in PSP and MSA, especially from the pro-inflam-
matory pathway, although the interaction between
pathways is complex. CRP followed the same pattern.
CRP is usually considered a liver-derived unspecific
acute phase reactant but also expressed in the CNS, and
one study found CRP to be synthesized in cell cultures
of microglia [20].
One aim of this study was to investigate the bio-
marker potential focusing on the clinically difficult
distinction between PD and MSA. PD and MSA often
present with similar symptomatology in the initial
phases of the diseases, and a valid biomarker would
have profound clinical impact. We achieved the best
diagnostic performance between MSA and PD pa-
tients with a subset of analytes (CRP, TNF-α, IL-1β,
IFN-γ). The best subset of analytes was identified in a
logistic regression model. Possible bias include overfit-
ting, and given the relatively small sample size, add-
itional studies are needed to validate.
Previously, CSF pro-inflammatory cytokines (IL-1β
and IL-6 [7], TNF-α [8]) have been reported to be upreg-
ulated in PD patients compared to controls. Our results
do not support the previous reports. A possible explan-
ation may be related to differences in control groups.
Table 2 CSF protein levels of inflammatory markers, total tau, and albumin index
Analyte PD MSA PSP Controls (SC)
CRP, mean (SD)b 5376.31 (4376.71) 8208.5 (3921.46) 8293.99 (4261.78) 6005.12 (4155.4)
IFN-γ, mean (SD) 1.35 (1.69) 1.33 (1.04) 2.11 (2.37) 3.09 (10.64)
IL-10, mean (SD) 4.57 (7.02) 4.71 (2.49) 6.18 (3.85) 5.66 (6.5)
IL-18, mean (SD) 47.85 (18.06) 53.25 (34.44) 50.52 (21.20) 45.30 (19.25)
IL-1β, mean (SD)b 2.82 (3.52) 3.58 (2.23) 4.96 (3.85) 2.60 (1.61)
IL-4, mean (SD)b 2.50 (2.21) 3.60 (2.22) 4.86 (3.90) 2.95 (1.90)
IL-6, mean (SD)b 53.41 (59.32) 86.98 (73.0) 102.53 (87.87) 61.74 (59.18)
TGF-β1, mean (SD) 1482.25 (407.20) 1435.18 (298.70) 1502.96 (416.43) 1518.89 (395.04)
TNF-α, mean (SD)b 79.78 (63.71) 106.80 (50.55) 127.21 (75.32) 87.65 (63.39)
Total tau protein, mean (SD)b 303.9 (213.9) 470.8 (242.6) 365.8 (187.5) 286.8 (196.4)
CSF protein, total, g/L, mean 0.53 0.52 0.54 0.42
CSF leukocytes, total, mean 2.91 1.50 2.16 2.60
Albumin index, mean 8.13 8.32 8.38 6.31
aKruskal-Wallis p < 0.05, Bonferroni corrected
bp < 0.05 chi-square. All concentrations are in pg/ml, with the exception of CSF protein
Fig. 2 ROC curves discriminating MSA and PD patients based on
the best subset of four analytes (CRP, TNF-α, IL-1β, IFN-y) and CRP
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However, in a recent study investigating TNF-α, among
others, in CSF, no significant differences were found be-
tween PD patients and a control patient group [21].
Confounding factors in our study included intake of
anti-inflammatory drugs and comorbidity [22]. In
addition, the distribution of gender, disease duration,
and age was skewed across patient groups, and it is
established that the systemic immune response changes
with aging [23]. Hence, we adjusted analysis for age, gen-
der, and use of anti-inflammatory drugs. We found no
correlation between disease duration and cytokines, and
PD patients presented with the longest disease duration.
The age-adjusted Charlson comorbidity index did not
differ significantly between patient groups.
Disease severity also must be addressed. We evalu-
ated disease severity on the HY rating scale. The bur-
den of pathology (neurodegeneration) reflects HY and
disease severity in PD [14]. The median HY score dif-
fered (insignificantly) between PD (HY median = 2)
and MSA and PSP (HY median = 3). However, the HY
scale emphasizes on axial symptoms and postural in-
stability. This may classify PSP and MSA with higher
scores than is reflected by the burden of pathology.
Disease severity and duration did not correlate within
the patient groups.
The strengths of the study were the well-characterized
patient cohort comprising for the orphan disorders of
MSA and PSP high number of patients. We had infor-
mation on important confounders and the CSF/plasma
albumin ratio. The CSF/plasma albumin ratio represents
a measure of possible blood-brain barrier leakage and
cytokines from the peripheral circulation entering the
CNS. We found no significant differences between
the patient groups. Lastly, as pre-analytical factors
may cause bias in biochemical studies due to differ-
ences in handling, sampling, or analyzing [24], it is
worth noting that all samples in this study were han-
dled similarly. No limit for blood contamination were
set for this study. Blood contamination could possibly
confound results. Hence, the first tubes were used for
routine investigation only, and samples were centri-
fuged at 2000g after sampling which in a previous
study [25] resulted in hemoglobin concentration
below 200 ng/ml in all samples.
Our study also had some limitations. Firstly, all diag-
noses were clinical, and since definite diagnosis requires
neuropathology, misclassification is a possibility. How-
ever, the follow-up time was substantial in our cohort.
Secondly, the control group included in this study was
associated with limitations. Our reference group com-
prised of patients with acute onset headache where the
CSF cytokine response, to our knowledge, is unknown. It
is possible that acute onset headache would increase the
CSF cytokine levels. Furthermore, data were available on
regular use of anti-inflammatory drugs, but we did not
have information on self-administered use of anti-in-
flammatory drugs, if any, prior to the admission, aiming
to relief the headache of controls. Moreover, the controls
were significantly younger than disease groups. Thirdly,
we only investigated selected CSF cytokines, and we may
have left out others of importance.
Conclusion
In this well-described cohort of PD, MSA, and PSP
patients, we analyzed a subset of inflammatory
markers (CRP and eight cytokines) in the cerebro-
spinal fluid. Our study revealed a significant increase
in pro-inflammatory and microglia-related cytokines
(TNF-α, IL-1β, IL-6), CRP, and IL-4 in MSA and PSP
patients compared to PD patients. No cytokine was a
specific marker for parkinsonism, but TNF-α, CPP,
IL-1β, IL-4, and IL-6 may be useful for early differenti-
ation of atypical parkinsonism to PD.
Additional file
Additional file 1: Table S1. Correlations between CRP and cytokine
levels and clinical data. Correlations between analytes and age,
disease duration, levodopa equivalents, Hoehn and Yahr stage, and
total-Tau presented with Spearman’s rho and Bonferroni-corrected p
values. (XLSX 10 kb)
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